- Home
- SAM vs ETNB Comparison
SAM vs ETNB Comparison
Compare SAM & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAM
- ETNB
- Stock Information
- Founded
- SAM 1984
- ETNB 2018
- Country
- SAM United States
- ETNB United States
- Employees
- SAM N/A
- ETNB N/A
- Industry
- SAM Beverages (Production/Distribution)
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- SAM Consumer Staples
- ETNB Health Care
- Exchange
- SAM Nasdaq
- ETNB Nasdaq
- Market Cap
- SAM 2.4B
- ETNB 2.2B
- IPO Year
- SAM 1995
- ETNB 2019
- Fundamental
- Price
- SAM $220.26
- ETNB $14.82
- Analyst Decision
- SAM Hold
- ETNB Buy
- Analyst Count
- SAM 10
- ETNB 10
- Target Price
- SAM $246.11
- ETNB $22.31
- AVG Volume (30 Days)
- SAM 201.0K
- ETNB 9.4M
- Earning Date
- SAM 10-23-2025
- ETNB 11-06-2025
- Dividend Yield
- SAM N/A
- ETNB N/A
- EPS Growth
- SAM N/A
- ETNB N/A
- EPS
- SAM 6.99
- ETNB N/A
- Revenue
- SAM $2,049,593,000.00
- ETNB N/A
- Revenue This Year
- SAM N/A
- ETNB N/A
- Revenue Next Year
- SAM $1.10
- ETNB N/A
- P/E Ratio
- SAM $31.53
- ETNB N/A
- Revenue Growth
- SAM 2.46
- ETNB N/A
- 52 Week Low
- SAM $185.34
- ETNB $4.16
- 52 Week High
- SAM $329.55
- ETNB $15.06
- Technical
- Relative Strength Index (RSI)
- SAM 51.62
- ETNB 79.24
- Support Level
- SAM $217.18
- ETNB $14.67
- Resistance Level
- SAM $227.37
- ETNB $14.89
- Average True Range (ATR)
- SAM 5.25
- ETNB 0.08
- MACD
- SAM 0.31
- ETNB 0.01
- Stochastic Oscillator
- SAM 63.25
- ETNB 49.09
About SAM Boston Beer Company Inc. (The)
Boston Beer is a top player in high-end malt beverages and adjacent categories in the US, with strong positions in craft beer, flavored malt beverages, hard cider, and hard seltzer. The bulk of volume and revenue is concentrated in four brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly. Beverages are produced using a hybrid model leveraging both in-house capacities and third-party breweries through contract arrangements. While the firm is required to use distributors to reach end markets, including retailers and on-premises operators, it also employs 500 internal sales representatives to educate the market about its products. The firm generates almost all sales in the US.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).